Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn:
”The FDA has approved our treatment for hemophilia A and B for two new patient populations following a priority review.
With this approval, children ages 6 to 11 with hemophilia B will have a subcutaneous, non-factor treatment option available for the first time.
Bringing a medicine discovered and developed by Pfizer to the people who need it most—guided at every step by patient need—is an important moment for our teams.
A special thank you to the Pfizer scientists who are continuing to advance care for people with hemophilia, and to the hemophilia patient community who participated in clinical trials that are instrumental to making advancements like this one happen.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 18, 2026, 17:48Ronak H. Mistry: Updated ASH Guidelines Bring New Focus to Iron Deficiency
-
Sep 18, 2026, 17:32Hassan Kawtharany: New Ferritin Cutoffs for the Diagnosis of Iron Deficiency With or Without Anemia
-
Sep 18, 2026, 17:20Abhishek G P: GAVE as an Important Cause of Chronic Gastrointestinal Blood Loss
-
Sep 18, 2026, 17:08Irem Karaman Sebin: ASH 2026 Changes a Key Concept in Iron Deficiency
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH